Serum transaminases in children with wilson’s disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 39, Issue 4, 2004, Pages 331-336

  Iorio, Raffaele ^a   D’Ambrosi, Mariangela ^b   Marcellini, Matilde ^b   Barbera, Cristiana ^b   Maggiore, Giuseppe ^b   Zancan, Lucia ^b   Giacchino, Raffaella ^b   Vajro, Pietro ^b   Marazzi, Maria Grazia ^b   Francavilla, Ruggiero ^b   Michielutti, Fabio ^b   Resti, Massimo ^b   Frediani, Tullio ^b   Pastore, Maria ^b   Mazzarella, Giuseppina ^b   Fusco, Giuseppina ^b   Cirillo, Francesco ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Copper; Liver disease; Patients compliance; Penicillamine; Zinc

Indexed keywords

ALANINE AMINOTRANSFERASE; PENICILLAMINE; ZINC;

ADOLESCENT; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; HUMAN; INFANT; LIVER; MALE; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; WILSON DISEASE;

ADOLESCENT; ALANINE TRANSAMINASE; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; INFANT; LIVER; MALE; PENICILLAMINE; RETROSPECTIVE STUDIES; ZINC;

EID: 30744436753     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-200410000-00006     Document Type: Article

References (34)

1. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993;5:344-50.
2. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003;37:1475-92.
3. Walshe JM, Dixon AK. Danger of non-compliance in Wilson’s disease. Lancet 1986;1(8485):845-7.
4. Sternlieb I. Perspectives on Wilson’s disease. Hepatology 1990;12:1234-9.
5. Yarze JC, Martin P, Munoz SJ, et al. Wilson’s disease: current status. Am J Med 1992;92:643-54.
6. Strickland G, Leu ML. Wilson’s disease: clinical and laboratory manifestation in 40 patients. Medicine 1975;54:113-7.
7. Sànchez-Albisua I, Garde T, Hierro L, et al. A high index of suspicion: the key to an early diagnosis of Wilson’s disease in childhood. J Pediatr Gastroenterolol Nutr 1999;28:186-90.
8. Iorio R, Porzio S, Mazzarella G, et al. Wilson disease: diagnostic dilemmas?J Pediatr Gastroenterol Nutr 2000;31:93-5.
9. Walshe JM. Penicillamine: a new oral therapy for Wilson’s disease. Am J Med 1956;21:487-95.
10. Walshe JM. Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643-7.
11. Brewer GJ, Dick R, Johnson V, et al. Treatment of Wilson’s disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 2001;137:191-8.
12. Van Caillie-Bertrand M, Degenhart HJ, Visser HK, et al. Oral zinc sulphate for Wilson’s disease. Arch. Dis. Child 1985;60:656-9.
13. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al. Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol 1991;48:42-7.
14. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson’s disease with ammonium tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545-54.
15. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Treatment of Wilson’s disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994;123:849-58.
16. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson’s disease with zinc: XV long-term follow up studies. J Lab Clin Med 1998;132:264-78.
17. Hoogenraad TU, Van Huttum J, Van De Hamer CJA. Management of Wilson’s disease with zinc sulphate: experience in a series of 27 patients. J Neurol Sci 1987;77:137-46.
18. Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson’s disease. Ann Intern Med 1983;99:314-20.
19. Rossaro L, Sturniolo GC, Giacon G, et al. Zinc therapy in Wilson’s disease: observation in five patients. Am J Gastroenterol 1990;85:665-8.
20. Friedman LS. Zinc in treatment of Wilson’s disease: how it works. Gastroenterology 1993;104:1566-8.
21. Menard MD, McCornick CC, Cousins RJ. Revolution of intestinal metallothionein biosynthesis in rats by dietary zinc. J Nutr 1981;111:1353-61.
22. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992;120:380-6.
23. Stremmel W, Meyerrose KW, Niederau C, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Int Med 1991;115:720-6.
24. Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr 1987;146:261-5.
25. Da Costa CM, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson disease. Hepatology 1992;15:609-15.
26. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 1992;71:139-64.
27. Van Caillie-Bertrand M, Degenhart HJ, Luijendijk I, et al. Wilson’s disease: assessment of D-penicillamine treatment. Arch Dis Child 1985;60:652-5.
28. Sternlieb I, Scheinberg H. Prevention of Wilson’s disease in asymptomatic patients. N Engl J Med 1968;278:352-9.
29. Iorio R, D’Ambrosi M, Mazzarella G, et al. Early occurrence of hypertransaminasemia in a 13-month-old child with Wilson disease. J Pediatr Gastroenterol Nutr 2003;36:637-8.
30. Stillman AE, Rohr LR. Persistent transaminasemia and fatty liver. Am J Dis Child 1982;136:242-4.
31. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al. Treatment of Wilson’s disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr 1993;12:26-30.
32. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997;61:317-28.
33. Okada T, Shiono Y, Hayashi H, et al. Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson’s disease. Hum Mutat 2000;15:454-62.
34. Wu ZY, Wang N, Lin MT, et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in Chinese patients with Wilson disease. Arch Neurol 2001;58:971-6